EMA Authorised: Omjjara (Momelotinib dihydrochloride monohydrate) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

EMA authorises Omjjara (momelotinib dihydrochloride monohydrate) for myeloproliferative disorders with splenomegaly; orphan medicine status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloproliferative Disorders
• Splenomegaly

Drugs mentioned

• Omjjara (momelotinib dihydrochloride monohydrate)

Snippet

Status: Authorised. Therapeutic area: Splenomegaly;Myeloproliferative Disorders. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 10/04/2026. Orphan medicine